|Rapid Review Complete
|Niraparib in combination with abiraterone acetate
|Niraparib in combination with abiraterone acetate and prednisone/prednisolone is indicated for the treatment of adults with metastatic castration resistant prostate cancer (mCRPC) and BRCA1/2 mutations (germline and/or somatic) in whom chemotherapy is not clinically indicated.
|Rapid review commissioned
|Rapid review completed
|Rapid review outcome
|A full HTA is not recommended. The NCPE recommends that niraparib in combination with abiraterone acetate not be considered for reimbursement at the submitted price*.
*This recommendation should be considered while also having regard to the criteria specified in the Health (Pricing and Supply of Medical Goods) Act 2013.
The HSE has approved reimbursement following confidential price negotiations. November 2023